Holen Sie sich die Stockscreener-App
37.45
5.70%
2.02
Vorhandelsmarkt:
37.45
Schlusskurs vom Vortag:
$35.43
Offen:
$35.8
24-Stunden-Volumen:
1.91M
Relative Volume:
0.76
Marktkapitalisierung:
$4.43B
Einnahmen:
$1.29B
Nettoeinkommen (Verlust:
$251.00M
KGV:
18.97
EPS:
1.9744
Netto-Cashflow:
$-193.86M
1W Leistung:
+2.29%
1M Leistung:
-3.93%
6M Leistung:
+7.82%
1J Leistung:
+173.96%
1-Tages-Spanne:
$35.57
$37.95
1-Wochen-Bereich:
$32.41
$37.95
52-Wochen-Spanne:
$13.42
$41.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
37.45 | 4.19B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.45 | 47.49B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.43 | 38.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.96 | 38.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.52 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.69 | 23.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Net margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Quick ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted net income available to common stockholders of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
After tax other income/expense of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Non-controlling/minority interest of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Operating income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted earnings per share (diluted EPS) of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – LSX:A42086 - TradingView
Cash per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
EBITDA margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY - The Globe and Mail
Indivior Pharmaceuticals Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 - GlobeNewswire Inc.
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
INDV Stock Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
What to Know About This Fund's $74.8 Million Indivior Sale - The Globe and Mail
Madison Avenue Partners Buys Large Stake in Indivior - HarianBasis.co
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% - The Globe and Mail
Indivior Pharmaceuticals, Inc. Balance Sheet – DUS:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – DUS:E7P - TradingView
Indivior Pharmaceuticals Inc. (INDV) upgraded to strong buy: Here's what you should know - MSN
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After A Strong Multi‑Month Share Price Run - Sahm
Bears are losing control over Indivior Pharmaceuticals Inc. (INDV), here's why it's a 'buy' now - MSN
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Free cash flow of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Equity in earnings of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:E7P - TradingView
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect? - Yahoo Finance
Indivior launches $175M accelerated share buyback - MSN
Indivior (INDV) Shows Benefits of Sublocade for Opioid Use Disor - GuruFocus
Debt to assets ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Net margin % of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Price to cash flow ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Preferred dividends of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – MUN:E7P - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Earnings and Revenue – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Balance Sheet – MUN:E7P - TradingView
Monthly addiction shot tied to fewer relapses, hospital visits - Stock Titan
The Bull Case For Indivior Pharmaceuticals (INDV) Could Change Following Upgraded Outlook And $175M BuybackLearn Why - Yahoo Finance
New Studies Show Adherence to Monthly Injectable - GlobeNewswire
Indivior Pharmaceuticals Inc. (INDV) is a great choice for 'trend' investors, here's why - MSN
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.69%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):